Please login to the form below

Not currently logged in
Email:
Password:

Ascletis

This page shows the latest Ascletis news and features for those working in and with pharma, biotech and healthcare.

Chinese biotechs aim PD-L1 antibody at hepatitis B

Chinese biotechs aim PD-L1 antibody at hepatitis B

viral diseases to Ascletis in China, potentially opening up a new revenue stream for the drug. ... Under the terms of the deal, Ascletis has agreed to pay an undisclosed upfront cash fee, plus milestones and royalties on any future sales in return for

Latest news

  • Roche invests in diagnostics in China Roche invests in diagnostics in China

    Roche has made other investments in China in recent years including a collaboration with Chinese-American biotech company Ascletis to help bring its hepatitis C virus (HCV) therapy danoprevir to market

  • Roche taps local expertise for hep C drug in China Roche taps local expertise for hep C drug in China

    Many of these are infected with HCV genotype 1b, a strain which has proved "highly responsive" to danoprevir, according to Ascletis. ... Commenting on the link-up with Ascletis, Luke Miels, head of Roche's Asia-Pacific pharma operations, said: "our

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Is China ready for a pharmaceutical gold rush?

    The first company to list, Ascletis Pharma Inc, was valued at $2bn when its IPO closed on 1 August. ... While some might have seen Ascletis’ fate as a market correction to the biotech stock hype, further IPOs don’t seem to be falling into line.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics